Disrupting the nNOS–PSD95 interaction could selectively inhibit the NMDARs-nNOS signal pathway, without blocking NMDARs function and catalytic activity of nNOS, thereby sparing unwanted effects on many other important physiological processes mediated by the NMDARs and nNOS. In this protocol, 4-(3,5-Dichloro-2-hydroxybenzylamino)-2-hydroxybenzoic acid, a nNOS-PSD95 interrupter, we named it ZL006, was prepared by the condensation of 3,5-dichlorosalicylaldehyde and 4-aminosalicylic acid, and the reduction of the condensation production with sodium borohydride. We synthesized the derivatives of ZL006 also.